Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Net Income (Common)
Iterum Therapeutics PLC
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Net Income (Common)
-$38.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Perrigo Company PLC
NYSE:PRGO
|
Net Income (Common)
-$12.7m
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Net Income (Common)
$414.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Net Income (Common)
-$160.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-14%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Net Income (Common)
-$35.6m
|
CAGR 3-Years
-329%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Net Income (Common)
€1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
See Also
What is Iterum Therapeutics PLC's Net Income (Common)?
Net Income (Common)
-38.4m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Net Income (Common) amounts to -38.4m USD.
What is Iterum Therapeutics PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
13%
Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for Iterum Therapeutics PLC have been 10% over the past three years , 13% over the past five years .